Go-ahead for LCT
Tuesday, 21 October, 2008
Living Cell Technologies [ASX: LCT] has received approval from the New Zealand Government to conduct a Phase I/IIa clinical trial of DiabeCell.
NZ's Health Minister, David Cunliffe, has approved the company's application, with the project to be monitored by his ministry.
A parallel Phase I/IIa trial commenced in Russia in 2007.
According to LCT, approval from the NZ Government will also make it easier to obtain approvals to trial the product in other companies.
DiabeCell uses insulin-producing porcine islet cells stored within LCT's proprietary encapsulation technology.
Organoid platform enables closer study of bat-borne viruses
Reconstructing bat organ physiology in the lab lets scientists explore how zoonotic viruses work...
Global study finds 250 genes linked to OCD
Researchers say they have found the genes linked to obsessive compulsive disorder (OCD), after...
TGA approves therapy for paediatric growth hormone deficiency
The TGA has approved SKYTROFA as a treatment for growth failure in children and adolescents aged...
